Amylin kept at neutral by Merrill

Merrill Lynch analyst Tom McGahren maintained Amylin Pharmaceuticals Inc. at neutral on news of positive top-line data from a label expansion study assessing the addition of Symlin at mealtime to a once-a-day basal (long acting) insulin regimen in type 2 diabetics. The company expects a supplemental New Drug Application filing by the end of the year. A label expansion could boost Merrill's Symlin peak sales estimate to $150 million to $175 million, from $120 million. Shares of the San Diego-based biopharmaceutical company were up 22 cents, or 0.49%, at $45.45. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.